).
Introduction
The microtubule-associated protein tau (MAPT), normally found in axons, is involved in microtubule polymerization and stabilization (Weingarten et al., 1975) . From one MAPT gene on chromosome 17q21 encoding 16 exons, six different tau protein isoforms are generated by alternative splicing in the adult human brain (Lee et al., 2001) . Tauopathies are neurodegenerative diseases defined by the presence of filamentous inclusions of hyperphosphorylated tau in neurons or glial cells (Ballatore et al., 2007) . Present evidence strongly suggests that the etiological spectrum of tauopathies ranges from monogenetic variants to predominantly environmental forms, with a rather large group of "sporadic" forms occupying the middle spectrum, where a genetic predisposition and hypothetical environmental triggers are probably jointly involved.
An example of an environmentally caused tauopathy is the atypical Parkinson syndrome endemic in Guadeloupe, linked to high consumption of nutritional products of Annonaceae plants (Caparros-Lefèbvre et al., 1999; Champy et al., 2005 Champy et al., , 2009 Lannuzel et al., 2007) . The implicated neurotoxins are Annonaceous acetogenins, a unique family of potent and lipophilic inhibitors of complex I of the respiratory chain (Bermejo et al., 2005) showing tropism towards mitochondria (Derbré et al., 2005; Kojima et al., 2010) . Annonacin, a prototypical representative of this class, causes neuronal loss and somatodendritic accumulation of phospho-tau in vivo and in vitro (Lannuzel et al., 2003; Champy et al., 2004; Escobar-Khondiker et al., 2007) . A systematic investigation of 24 globally distributed lipophilic complex I inhibitors has demonstrated a correlation between their potency to inhibit mitochondrial complex I with their potency to induce somatodendritic redistribution of phosphorylated tau protein in cultured rodent striatal neurons (Höllerhage et al., 2009 ). Finally, a number of studies in patients with progressive supranuclear palsy, a prototypical tauopathy, using different methodological approaches, point to a primary impairment of mitochondrial energy metabolism (Martinelli et al., 2000; Swerdlow et al., 2000; Albers et al., 2001; Stamelou et al., 2009) . Together, these clinical and experimental observations suggest that that complex I inhibition could contribute to pathogenic mechanisms in some sporadic tauopathies.
At the other end of the spectrum, 44 pathogenic MAPT mutations have been associated with a wide range of autosomal dominantly inherited tauopathies, as the frontotemporal dementias with parkinsonism linked to chromosome 17 (FTDP-17-Tau; Foster et al., 1997; Lee et al., 2001) . Typically, the neuropathological findings consist of frontotemporal neuronal loss and gliosis with intraneuronal neurofibrillary tangles (NFTs) and, occasionally, glial tau deposits ( van Swieten et al, 1999; Lindquist et al., 2008) . Interestingly, distinct clinical presentations may occur in association with the same mutation (Lee et al., 2001; Reed et al., 2001; Baba et al., 2005) , even within the same family (Bird et al., 1999) , suggesting that additional genetic or environmental modifiers contribute to the determination of the final clinical and neuropathological phenotype.
The R406W mutation is a particularly interesting MAPT missense mutation in exon 13 (Arg 406 to Trp, numbered according to the longest tau isoform), first described in North America (Reed et al., 1997; Hutton et al., 1998) , later in the Netherlands  van , Belgium (Rademaker et al., 2003) , Sweden Passant et al., 2004) , Denmark (Lindquist et al., 2008 (Lindquist et al., , 2009 and Japan (Ikeuchi et al., 2008) .
High variability in the clinical manifestation has been described between and within R406W kindreds. Age of onset varied from 45 to 75 years and most studied cases initially resemble Alzheimer disease (AD) with early memory impairment, with frontal lobe symptoms and language problems appearing later (Reed et al., 1997; Lindquist et al., 2008) . However, some patients showed frontal personality changes as the earliest and most striking feature with the presence of parkinsonian symptoms being variable (Reed et al., 1997; van Swieten et al., 1999) .
The phenotypic variability of inherited tauopathies suggests the presence of environmental modifiers. Potential candidates are toxins already implicated in environmental variants of tauopathies. Searching for gene-environment interactions leading to pathogenic synergy, we investigated therefore the effects of annonacin in mice overexpressing the longest human tau isoform with the R406W mutation (Zhang et al., 2004) .
Methods

Animals
R406W
+/+ transgenic mice breeder pairs were donated by Dr. Virginia M.-Y. Lee, University of Pennsylvania School of Medicine (Philadelphia, USA). Their full description is given at Zhang et al. (2004) . Briefly, the longest human tau isoform containing the R406W mutation was cloned into the mouse prion promoter (MoPrP.Xho) expression vector at the XhoI site, and fertilized in a mixed C57BL6 x C3H (B6C3/F1) strain background.
Homozygous R406W +/+ and non-transgenic wild-type (R406W -/-) mice used were kept in the same B6C3 background. Only males were used in the experiments. The genotype was confirmed by genomic DNA samples isolated from the tails using a peqGold tissue DNA extraction kit (PEQLAB, Erlangen, Germany). Cerebral expression of the mutated human protein was confirmed by Western blots.
Complex I inhibitor
Annonacin was obtained from fruit pulp of Annona muricata, as described . The purity of this compound was confirmed by analytical reversed-phase HPLC-DAD/ESI-Q-MS.
Annonacin exposure
The animal work was approved by the appropriate governmental authority (Regierungspräsidium Giessen, mortality within 3 days of exposure and was not further pursued. Animals were weighted before and after the 3-day infusion period.
Tissue preparation
After the 3-day infusion period, mice received a lethal dose of 200 mg/kg of sodium pentobarbital i.p. and were perfused transcardially with ice-cold 0.1 M phosphate-buffered saline (PBS) for 2 minutes. Thereafter, the brains were quickly removed. The hemispheres were separated by a mid-sagittal cut. One hemisphere was post-fixed in 4% (wt/vol) paraformaldehyde in 0.1 M PBS for 24 h, cryoprotected in 10% (wt/vol) sucrose in 0.1 M PBS for 48 h, frozen in isopentane at -30°C for 2 min and stored at -80°C for histology. The other hemisphere was immediately dissected, frozen in -30°C isopentane and stored at -80°C for western blotting, measurement of proteasomal proteolytic activities and quantitative PCR. A minimum of three samples per treatment group was analyzed in each assay.
Immunohistochemistry
Brains were cut into 40-µm sections using a cryostat (Leica, Wetzlar, Germany), collected in 10 regularly spaced series, and stored in 0. Laboratories, Burlingame, CA, USA; 1:200). Bound antibodies were visualized with 0.5 mg/ml of 3,3'-diamino-benzidine-tetrachloride (DAB, Sigma-Aldrich, Munich, Germany). To exclude non-specific labeling, the primary antibodies were omitted.
Image analysis
Phospho-tau labeled neurons were analyzed in 5-7 animals per group for R406W -/-and 10-12 per group for R406W +/+ . Neu-N labeled neurons and Iba1 labeled microglia were analysed in 3-5 animals per group.
Stereological cell counts were done by an observer blinded to the animals' identity on Fototechnik, Buchen, Germany). Pictures were analysed using Image-J software (U.S. National
Institutes of Health, MD, USA, http://imagej.nih.gov/ij) to measure the mean grayness of C2/C3 region, from which the background grayness of the molecular layer was subtracted.
Western blots
Proteins were extracted in commercial tissue lysing buffer (T-PER Tissue Protein
Extraction Reagent, Thermo Scientific, Rockford, USA) containing inhibitors of proteases and phosphatases (Halt Protease Inhibitor Cocktail, Halt Phosphatase Inhibitor Cocktail, 1% each, Thermo Scientific). After centrifugation (10,000 x g, 4°C, 5 min), supernatants were recovered and separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis.
To prepare sarkosyl-insoluble protein extracts, the remaining pellets were further processed according to Delobel et al. (2008) anti-p25, 1:1000, anti-Cdk5, 1:50000, anti-ß-actin, 1:1000 (Santa Cruz, Santa Cruz, USA).
Immunoreactivity was revealed with the chemiluminescent substrate kit (Pierce ECL Western Blotting Substrate, Thermo Scientific) and exposed on x-ray films (Amersham Hyperfilm TM ECL, GE Healthcare).
Proteasomal peptidase activities
Brain samples collected from frontal cortex of R406W -/-and R406W +/+ mice treated GCTCCAAAGACACCACCCA; reverse: GCTGTAGCCGCTGCGATC) and one amplifying both human and mouse MAPT cDNA (forward: GGCTCCACTGAGAACCTGAA; reverse:
CCGGGACGTGTTTGATATT) were designed using primer Express 1.0. β-actin (forward:
CTGTGTGGATCGGTGGCTC, reverse: CTGCTTGCTGATCCACATCTG) was used as control gene. Each sample was run in triplicate on an ABI PRISM 7500 Detection system (Applied Biosystems) and three different experiments were used for final quantifications.
Statistical analysis
For statistical analysis we used GraphPad Prism 5.0 (La Jolla, CA, USA). Results were expressed as mean ± SEM. A p-value < 0.05 was assumed to be statistically significant. The experimental groups were compared with a one-way analysis of variance (ANOVA) with the Newman-Keuls post-hoc test, or two-way ANOVA followed by a post-hoc least significant difference (LSD) test, as appropriate.
Results
Annonacin-induced mortality
Vehicle-treated animals showed no mortality. Both R406W -/-or R406W +/+ mice, treated with doses of 6 and 9 mg/kg/day of annonacin for 3 days, had a mortality rate of 6-13%.
Annonacin increases phospho-tau in neuronal somata in R406W
Vehicle-treated R406W -/-mice at 16-18 weeks of age had very low detectable levels of phospho-tau staining using the antibodies AT8 ( Figure 1 ) and AT180 (Figure 2 ) in the cortex, hippocampus and amygdala. In vehicle-treated R406W +/+ mice of the same age, higher levels of AT8 and AT180 immunoreactivity were observed in the cerebral neuropil ( Figures 1 and 2) ; in the cortex, many pyramidal neurons were stained in their soma and apical dendrites; in the hippocampus and amygdala phospho-tau labeling was more localized in the soma; in the hippocampus, AT8 and AT180 labeling was more intense in the pyramidal layer of CA3 region, with some animals also exhibiting labeling through CA1 region.
Three days of systemic annonacin exposure did not significantly alter the AT8 and In the amygdala, neuronal somata were already intensely AT8-and AT180-immunoreactive in vehicle-treated R406W +/+ mice and annonacin exposure had no significant additional effect on phospho-tau labeling (not shown). Other brain regions examined in R406W +/+ mice, such as striatum, midbrain and cerebellum had no obvious accumulation of phospho-tau in neurons after annonacin-treatment. In no brain region analyzed, we observed AT8 or AT180 immunoreactivity in glial cells.
Immunohistochemistry with the AT100 and AT270 antibodies gave no signal in vehicle-treated R406W -/-mice and labeled neuropil (AT270) or nuclei (AT100) in R406W
+/+ mice. However, somatodendritic accumulation of phospho-tau was not detected with the AT100 and AT270 antibodies in vehicle-or annonacin-treated R406W -/-or R406W +/+ mice (not shown). With the AD2 antibody, very low levels of immunoreactivity were detected in R406W +/+ mice, mainly localized in a few neurons in the deeper layers of the neocortex; no significant alteration was observed upon annonacin treatment (not shown).
Annonacin increases tau protein levels in R406W +/+ , but not in R406W -/-mice
In order to check whether an increase in tau protein levels contributes to the observed neuronal accumulation of phospho-tau, we performed Western blot analysis in brain tissue extracted from mice treated with 6 or 9 mg/kg/d of annonacin or vehicle.
T14 and HT7 antibodies, recognizing specifically human tau, gave no signal in the frontal cortex in R406W -/-mice (not shown). Expectedly, both antibodies labeled a single band of human tau (the transgene) at 67-69 kD in R406W +/+ mice. This band showed a significant increase upon annonacin treatment ( Figure 3A -B).
The Tau5 antibody, which recognizes both mouse and human tau isoforms, demonstrated that annonacin exposure increased the amount of total tau in R406W +/+ , but not in R406W -/-mice ( Fig. 3C-D) . With the Tau5 antibody, two bands were strongly labeled at 67-69 kD and 52-54 kD in R406W +/+ mice, while only the lower kD band was intensely labeled in R406W -/-mice (Fig. 3D) . Therefore, the longer isoform corresponds mainly to human tau, while the shorter isoform corresponds mainly to mouse tau; annonacin exposure increased both long and short isoforms in R406W +/+ ( Figure 3E ), but did not increase the short isoform in R406W -/-mice. As control, we checked -synuclein protein levels, which did not change under annonacin treatment in R406W +/+ and R406W -/-mice ( Figure 3D ,F).
To determine whether the annonacin-induced increase in total tau was due to augmentation of expression at the transcriptional level, tau mRNA levels were measured by quantitative PCR in cortical tissue from annonacin-intoxicated versus vehicle-exposed animals.
The results demonstrated that annonacin does not alter the expression of mouse ( Figure 3G) and human tau ( Figure 3H ). This suggests that the observed increase in tau protein levels is therefore regulated at a posttranscriptional level.
Impairment of tau degradation could contribute to the annonacin-induced accumulation of tau protein by a mechanism involving the inhibition of the ubiquitin-proteasome system, since tau is mainly degraded by this system (David et al., 2002; Goldbaum et al., 2003; Poppek et al., 2006) . In order to test this hypothesis, the proteasomal proteolytic activities were measured in cortical tissue from annonacin-intoxicated versus vehicle-exposed animals from both R406W +/+ transgenic and non-transgenic mice lineages. The results showed that annonacin intoxication with 9 mg/kg/d inhibits proteasomal chymotrypsin-like (LLVY) and peptidylglutamyl-peptide hydrolase (LLE) activities in R406W +/+ transgenic, but not in nontransgenic mice ( Figure 3I ).
In summary, annonacin increased both mouse and human transgenic tau protein levels in R406W +/+ , but not in R406W -/-mice, putatively by reduced proteasomal degradation. Figure 4A ), but not of R406W -/-mice (not shown).
Annonacin increases the amount of insoluble and phospho-tau in R406W
In order to further characterize the effect of annonacin exposure on tau, we compared the amount of phospho-tau in the soluble fraction of homogenates of cortical tissue extracted from R406W +/+ and R406W -/-mice exposed to annonacin or vehicle. Protein levels of phospho-tau labeled at the AT8 or AT180 epitopes were increased after annonacin exposure in R406W +/+ , but not in R406 -/-mice ( Figure 4B , C, F). Both long and short tau isoforms labeled with AT8 ( Figure 4D ) and AT180 ( Figure 4G ) were increased in R406W +/+ ; the effect was observed with both the lower (6mg/kg) and the higher dose (9 mg/kg) of annonacin exposure, suggesting that annonacin increased the amount of phosphorylated transgenic human tau and of phosphorylated endogenous mouse tau in R406W +/+ transgenic mice, but not in R406W -/-mice.
The ratio between AT8/Tau5 ( Figure 4E ) and AT180/Tau5 ( Figure 4H ) increased significantly with annonacin exposure in R406W +/+ mice, suggesting that annonacin increased phosphorylation of tau levels more than just explained by the increase in total tau protein. As control, we assessed the levels of β-actin in both R406W +/+ and R406W -/-mice which showed no increase after annonacin exposure ( Figure 4B , bottom row).
Annonacin exposure alters the levels of tau kinases
An increase in phospho-tau could have resulted from an overactivation of tau kinases.
Therefore, we tested the hypothesis whether annonacin intoxication alters tau kinases.
Candidate tau kinases were selected based on their capacity to phosphorylate tau at both the AT8 and AT180 sites (Hanger et al., 2009) . Western blot analysis in frontal cortex samples were performed for the kinases SAPK, MAPK (Erk1/2), GSK-3β, and Cdk5.
Annonacin intoxication increased the levels of SAPK in both R406W +/+ and R406W -/-mice in a dose-dependent manner ( Figure 5A, B) . The protein levels of MAPK and GSK-3 increased only in R406W +/+ mice, but only after 9 m/kg annonacin treatment ( Figure 5A , C, D). Levels of phosphorylated forms of GSK-3β at both activating and inactivating sites were also increased in R406W +/+ after annonacin treatment, but only with 6 mg/kg ( Figure 5A , E, F).
Protein levels of Cdk5 increased in both R406W +/+ and R406W -/-in a dose-dependent manner ( Figure 5A , G). Activation of Cdk5 requires its association with p35 or p39; a truncated form of p35, called p25, is responsible for an overactivation of Cdk5 and has been associated with tau hyperphosphorylation (Cheung and Ip, 2012) . We observed a striking increase in the p25/p35 ratio, selectively in R406W +/+ after annonacin exposure, 10-fold at low and 20-fold at high toxin doses ( Figure 5A , H-J).
Annonacin exposure did not cause neuronal death nor microglial reaction
Histological assessment through quantification of the number of NeuN-immunoreactive neurons demonstrated that a 3-day annonacin intoxication was not sufficient to cause neuronal cell death in R406W +/+ nor in R406W -/-mice in the brain regions analysed (Figure 6 ).
Statistical analysis (2-way ANOVA, post hoc-Bonferroni test) demonstrated significant interaction between mice genotype and annonacin treatment for frontal cortex data ( Figure 6 A-B; F=3.84; p=0.046), but not for parietal cortex ( 
Discussion
The R406W is an FTDP-17 mutation associated with relatively late onset and long disease duration; although the initial clinical setting resembles AD, frontal lobe symptoms may prevail later in the disease . Transgenic mice carrying the human R406W mutation show an age-dependent somatodentritic accumulation of phosphorylated tau in the neocortex, hippocampus, cerebellum and spinal cord, and NTF-like inclusions were detected at 12 months, but not at 6 months of age (Zhang et al., 2004) . The R406W +/+ mice used in our study were 16 to 18-week old at the time of sacrifice. It seemed an appropriate window to introduce a toxin to assess its effects on the pathological phenotype, because the animals would
not have yet developed intense tau pathology or any discernible behavioral deficits at this time point.
Previous work has shown that low nanomolar concentrations of annonacin cause neuronal cell death and induce tau redistribution from the axon to the cell body of striatal neurons in vitro . These effects were shown to be associated with annonacin-induced ATP reduction . Höllerhage et al. (2009) have extended the findings to additional natural complex I inhibitors, demonstrating their capacity to induce redistribution of phospho-tau to the somatodendritic compartment in good correlation with their capacity to reduce ATP levels. These in vitro models employed fetal neurons, in which tau is physiologically more phosphorylated than in adult neurons (Goedert et al. 1994) , thus annonacin did only cause a redistribution of phospho-tau, but not a measurable increase in tau phosphorylation .
In proteolytic activity in our present in vivo experiments, and since tau can be degraded by the proteasome (David et al., 2002; Goldbaum et al., 2003) , we suggest that annonacin increases total tau level, apparently by reducing proteasomal degradation, but not by increasing tau expression.
Proteasome inhibition and tau protein increase after annonacin exposure was surprisingly only occurring in R406W +/+ , but not in R406W -/-mice. The excess of proteolytic demand by overexpression a mutated human tau protein in R406W +/+ transgenic mice may already challenge the ubiquitin-proteasome system (UPS) to its limits. There is also evidence that hyperphosphorylation of tau impairs its degradation by the proteasome (Poppek et al., 2006 ) and the addition of oxidative stress induced by complex I inhibition imposes an additional challenge to the UPS, as shown previously . The combination of these factors may overwhelm the clearance capacity of the UPS, leading to tau accumulation. Consistently, we observed no accumulation of the α-synuclein protein, which is predominantly degraded by autophagy rather than the UPS in neuronal cells (Vogiatzi et al., 2008) .
There is evidence that the R406W mutation is less phosphorylated than the WT tau, especially at the Ser396 and Ser404 phosphorylation sites, which are in close proximity to the mutation (Perez et al., 2000; Miyasaka et al., 2001; Zhang et 2004) . Consistently, we have detected very low levels of AD2 immunoreactivity in R406W +/+ mice, and no significant alteration upon annonacin treatment. On the other hand, we have observed that hyperphosphorylation of tau at the AT8 and AT180 sites was increased after annonacin exposure in R406W +/+ mice, and that this increase was not explained by a mere augment in tau protein levels, since the increase in phospho-tau significantly exceeded the increase in total tau.
Thus, increased phosphorylation by activation of kinases is likely occurring upon annonacin treatment. We therefore asked which kinases were possibly implicated. We studied candidate kinases known to phosphorylate tau at the AT8 and AT180 site (Hanger et al., 2009 ). The protein levels of SAPK and Erk1/2 were increased by annonacin treatment in both R406W
+/+ and R406W -/-mice, and thus unlikely account for the observed tau phosphorylation, which occurred only in R406W +/+ , but not in R406W -/-mice. GSK-3 protein level was increased in R406W +/+ , but not in R406W -/-mice, at the high annonacin dose. This result correlates with the AT180/Tau5 ratio, which was also increased at the high annonacin dose, suggesting that GSK-3 might be implicated in tau phosphorylation at the AT180-reactive T231 epitope. The effect of GSK-3 at the low annonacin dose remained inconclusive, because the GSK-3 protein level remained unaltered, and phosphorylation of GSK-3was increased at both activating and inactivating sites. The Cdk5 protein level was increased in both R406W +/+ and R406W -/-mice at both annonacin concentrations. The ratio p25/p35 (Cdk5 activator/inhibitor), however, was only increased in R406W +/+ mice, 10-fold and 20-fold at the low and high annonacin dose, respectively. This result correlates with AT8/Tau5 ratio suggesting that Cdk5 might be implicated in tau phosphorylation at the AT8-reactive S202/T205 epitope.
Therefore, GSK-3 and Cdk5 are likely candidates for the observed annonacin effects in R406W +/+ mice. These two kinases are proline-directed serine/threonine kinases and are considered to be the major enzymes involved in tau phosphorylation at disease-related sites, especially in abnormal tau hyperphosphorylation in AD (Plattner et al., 2006; Sengupta et al., 2006) . Many studies have revealed intriguing functional associations between GSK-3 and Cdk5. The AT180 site T231, which was highly phosphorylated in our annonacin experiments, is phosphorylated by GSK-3but the phosphorylation was shown to be more intense when tau is pre-phosphorylated by Cdk5 at S235 (Sengupta et al., 1997; Cohen et al., 2004) . Prephosphorylation of tau by Cdk5 stimulates both the rate and the extent of a subsequent phosphorylation catalyzed by GSK-3 (Sengupta et al., 1997) . In our R406W +/+ mice, the Cdk5 activating ratio p25/p35 was significantly increased at low annonacin doses, whereas both Cdk5 and GSK-3 were activated after high annonacin doses, and consistently there was a significant increase in AT180 labeling.
On the other hand, Cdk5 has also been implicated in a regulatory role onto GSK3activation (Plattner et al., 2006; Cheung and Ip, 2012) . It has been shown in some studies in vivo and in vitro that over-activation of Cdk5 leads to inhibition of GSK-3, or the reverse, that the decreased activity of Cdk5 parallels the enhancement of GSK-3 activity (Hallows et al., 2003; Vandebroek et al., 2005; Plattner et al., 2006) . It has been argued that hyperphosphorylation of sites such as AT8 and PHF-1 is not due to a direct action of Cdk5, but is rather a consequence of loss of inhibitory control of GSK3- by Cdk5; such loss was observed in aged mice and associated with increased levels of p25 (Plattner et al., 2006) . In our experiments the p25/p35 ratio paralleled the AT8/Tau5 ratio suggesting that increased Cdk5 levels might be implicated in this tau phosphorylation. Another possibility would be that the increased levels of p25 impaired the Cdk5 inhibition over GSK-3, and the latter would then directly hyperphosphorylate tau at AT8 site. Additional studies will be necessary to elucidate the mechanism underlying annonacin effects on tau hyperphosphorylation.
In non-exposed R406W +/+ mice, phospho-tau staining exhibited a homogeneous aspect with no intracellular fibrillar deposits. Annonacin exposure increased the number of neurons with somatodentritic accumulation of phospho-tau, but did not affect the aspect of the staining, which remained homogeneous within the cytoplasm. Although we have detected an increase in the sarcosyl-insoluble fraction of total and phospho-tau in brain homogenates of annonacintreated R406W +/+ mice, we have not observed any structures that morphologically resembled NFT in brain sections. Pathological activity of cytosolic non-fibrillized hyperphosphorylated tau has been reported in several animal models that express human tau suggesting that tau fibrillization or the presence of NFT is not necessary for neurodegeneration (Wittmann et al., 2001; Santacruz et al., 2005) . Although we have not observed neuronal cell death, astroglial or microglial reactions, the brief period of annonacin treatment used in our study was enough to accelerate tau changes expected due to the overexpression of the transgene alone. In this regard, annonacin exposure changed the course of the disease and provoked an effect equivalent to an acceleration of the aging process. Consistently, we have also observed tau alterations in other tau-transgenic mice lines, using other complex 1 inhibitors, and also in different exposure protocols (e.g. more chronic and oral administration), but the presentation of these results would be beyond the scope of the present work.
In summary, we have shown that a brief 3-day exposure with annonacin, a natural lipophilic mitochondrial complex I inhibitor, is sufficient to increase tau protein levels, to alter tau kinases, to increase tau phosphorylation and to increase neuronal somatodendritic accumulation of phospho-tau in transgenic mice overexpressing human R406W-mutant tau, demonstrating that an environmental factor can change the course of the disease determined by a genetic factor. identified by Western blots using the antibodies T14 and HT7, are increased in R406W +/+ mice after 6 mg/kg (T14, * p= 0.015; HT7, * p=0.045) and 9 mg/kg (T14,* p=0,002; HT7, * p=0.031) of annonacin treatment in comparison to vehicle. C,D, With the Tau5 antibody, which labels both human and endogenous mouse tau, the effect was also observed in R406W of R406W +/+ , but not R406W -/-mice, annonacin caused a dose-dependent increase in AT8-labeled phospho-tau (B,C, 6 mg/kg, * p=0.004; 9 mg/kg, * p=0.026), affecting both the long (human, 6 mg/kg, * p=0.007; 9 mg/kg, * p=0.010 ) and short (mouse, 6 mg/kg, * p=0.002 ; 9 mg/kg, * p=0.042) isoform (B,D); β-actin protein levels are shown as loading controls. E, The ratio of AT8-reactive phospho-tau to Tau5-reactive total tau was also significantly increased in R406W +/+ (6 mg/kg, * p=0.011; 9 mg/kg, * p=0.002), but not R406W -/-mice. B,F-H, The phospho-tau antibody AT180 yielded similar results. F: 6 mg/kg, * p=0.011; 9 mg/kg, * p=0.001; G: long, 6 mg/kg, * p=0.003; 9 mg/kg, * p=0.001; G: short, 6 mg/kg, * p=0.038; 9 mg/kg, * p=0.002; H: 9 mg/kg, * p=0.007. * p<0.05, ANOVA followed by post hoc LSD test, annonacin vs. vehicle. A,B, SAPK levels were increased after both annonacin doses in both R406W +/+ (6 mg/kg, * p=0.036; 9 mg/kg, * p=0.034) and R406W -/-mice (6 mg/kg, * p=0.012; 9 mg/kg, * p=0.004).
A,C, Erk1/2 levels were increased only in R406W +/+ mice after 9 mg/kg annonacin exposure (* p=0.021). A,D-F, GSK-3β total protein levels were increased only in R406W +/+ mice after 9 mg/kg annonacin exposure (* p=0.046). GSK-3β phosphorylated both at Y216 leading to activation (E) and at S9 leading to inactivation (F) was increased only in R406W +/+ mice after 6 mg/kg annonacin treatment (E: phosphoY216, * p=0.046; F: phosphoS9, p=0.003). A,G, Cdk5 protein levels were increased after both the low and high annonacin doses in both R406 +/+ (6 mg/kg, * p=0.046; 9 mg/kg, * p=0.005) and R406W -/-(6 mg/kg, * p=0.013; 9 mg/kg, * p=0.021) mice. A,H-J, In R406W +/+ , but not in R406W -/-mice, after annonacin exposure, there was a decrease in p35 levels (H: 6 mg/kg, * p=0.02; 9 mg/kg, * p=0.018) along with an increase in p25 levels (I, (6 mg/kg, * p=0.027; 9 mg/kg, * p=0.03), resulting in an increase in the p25/p35 ratio (J, (6 mg/kg, * p=0.049; 9 mg/kg, * p=0.045), reaching approximately 10-fold of normal levels at low and 20-fold at high toxin doses. In R406W -/-mice, 9 mg/kg annonacin resulted in decrease in both p35 (H, * p=0.004) and p25 (I, * p=0.027). * p<0.05, ANOVA followed by post hoc LSD test, annonacin vs. vehicle. frontal cortex p=0.000, parietal cortex p=0.001, hippocampus p= 0.000), whereas annonacin treatment had no effect. Scale bars: 50 µm in B and D; 100 µm in F. 
